⚖
Compare Funds
See how two funds stack up side by side, real returns, risk, cost and portfolio overlap.
VS
Key Metrics Comparison
| Metric | DSP Healthcare Fund - Growth - Direct Plan | HDFC Pharma and Healthcare Fund - Growth - Direct Plan |
|---|---|---|
| Snapshot | ||
| AMC | DSP MF | HDFC MF |
| Category | Equity - Sectoral Fund - Pharma & Health Care | Equity - Sectoral Fund - Pharma & Health Care |
| NAV | ₹50.24 (29 Oct 2026) | ₹21.95 (30 Oct 2026) |
| Rating | ★★★★★ | ★★★★★ |
| Benchmark | BSE Health Care - TRI | BSE Health Care - TRI |
| Fund Manager | Chirag Dagli | Nikhil Mathur |
| Inception | 30 Nov 2018 | 04 Oct 2023 |
| Returns | ||
| 1Y | 15.40% | 22.64% |
| 3Y | 21.70% | 30.41% |
| 5Y | 16.25% | — |
| Since Inception | 22.61% | 29.15% |
| Risk | ||
| 13.78 | 14.07 | |
| 0.58 | 0.59 | |
| 1.04 | 1.59 | |
| 14.33 | 21.67 | |
| 2.33 | 3.48 | |
| -8.41% | -9.23% | |
| Costs | ||
| Expense Ratio | 0.75% | 1.03% |
| Exit Load | 0.50% on or before 1M, Nil after 1M | 1% on or before 30D, Nil after 30D |
| Min SIP | ₹100 | ₹100 |
| Min Lumpsum | ₹100 | ₹100 |
| Lock-in | None | None |
Min SIP is reported per fund, not per plan, every plan of a fund shares the same figure.
Portfolio Overlap
DSP MF73%
HDFC MF73%
27.1%Only 27.1% of holdings by weight are common between DSP MF and HDFC MF, based on each fund's top 20 disclosed holdings, not the full portfolio.
Common holdingDSP MFHDFC MF
Sun Pharmaceutical Industries Ltd.7.44%8.28%
Alkem Laboratories Ltd.4.75%4.64%
Divi's Laboratories Ltd.4.17%9.39%
Cipla Ltd.7.18%4.15%
Apollo Hospitals Enterprise Ltd.6.07%3.69%
Ipca Laboratories Ltd.8.13%2.98%
Category context: Equity vs Equity. Open the full Screener →